注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Anthera Pharmaceuticals, Inc.(Anthera)是一家生物制药公司,专注于开发和销售用于治疗炎症相关严重疾病(包括酶替代疗法和自身免疫性疾病)的产品。该公司拥有两个III期候选产品,liprotamase(也称Sollpura)和blisibimod。Sollpura是一种用于治疗胰脏外分泌功能不足(EPI)(常见于囊肿性纤维化及其他病症)患者的非猪研究性胰酶补充治疗(PERT)产品。Blisibimod靶向B细胞激活因子(BAFF)。该公司已通过一系列B细胞介导的自身免疫疾病(包括红斑性狼疮(SLE)或狼疮、IgA肾病及狼疮性肾炎等)实验评估BAFF。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Christopher S. Henney | 81 | 2005 | Independent Director |
David E. Thompson | 74 | 2005 | Independent Director |
Jeffrey Wagener | - | - | Member of Scientific Advisory Board |
David Wofsy | - | 2008 | Member of Scientific Advisory Board |
John Craig Thompson | 55 | 2016 | CEO & Director |
Michael Wilschanski | - | - | Member of Scientific Advisory Board |
Paul F. Truex | 53 | 2004 | Executive Chairman |
Michael W. Konstan | - | - | Member of Scientific Advisory Board |
Joan T. Merrill | - | - | Member of Scientific Advisory Board |
Philip T. Sager | 66 | 2014 | Independent Director |
Jonathan Barratt | - | - | Member of Scientific Advisory Board |
Brent V. Furse | 53 | 2016 | Independent Director |
Kenneth Kalunian | - | 2008 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核